彭博利珠单抗联合来伐替尼治疗 Epstein-Barr 病毒相关肝内胆管癌的显著疗效：病例报告

IF 5.4 3区材料科学 Q2 CHEMISTRY, PHYSICAL

ACS Applied Energy Materials Pub Date : 2024-04-22 DOI:10.1080/15384047.2024.2338644

Lisha Li, Dandan Yu, Jinru Yang, Fangyuan Zhang, Dejun Zhang, Zhenyu Lin, Meng-lan Zhai, Jing Wang, Tao Zhang, Lei Zhao

{"title":"彭博利珠单抗联合来伐替尼治疗 Epstein-Barr 病毒相关肝内胆管癌的显著疗效：病例报告","authors":"Lisha Li, Dandan Yu, Jinru Yang, Fangyuan Zhang, Dejun Zhang, Zhenyu Lin, Meng-lan Zhai, Jing Wang, Tao Zhang, Lei Zhao","doi":"10.1080/15384047.2024.2338644","DOIUrl":null,"url":null,"abstract":"ABSTRACT Background The prognosis for advanced intrahepatic cholangiocarcinoma (iCCA) is poor, and there remains an urgent need to develop efficient systemic therapy. The efficacy of Pembrolizumab immunotherapy combined with lenvatinibin in iCCA is still unclear. The role of Epstein–Barr-virus (EBV) as a biomarker in iCCA for response to immunotherapy needs further exploration. Case presentation We report a case of a 60-year-old female with EBV-associated advanced iCCA (EBVaiCCA) who progressed after first-line therapy. She accomplished an available response to the combination therapy of pembrolizumab with lenvatinib, with overall survival of 20 months. Conclusions As far as we know, this is the first case report about the application of Pembrolizumab with lenvatinib for EBVaiCCA patients. This case indicates that the combination of immunotherapy and antiangiogenic therapy provides a glimmer of hope for advanced EBVaiCCA patients.","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Significant response to pembrolizumab plus lenvatinib in Epstein–Barr-virus-associated intrahepatic cholangiocarcinoma: a case report\",\"authors\":\"Lisha Li, Dandan Yu, Jinru Yang, Fangyuan Zhang, Dejun Zhang, Zhenyu Lin, Meng-lan Zhai, Jing Wang, Tao Zhang, Lei Zhao\",\"doi\":\"10.1080/15384047.2024.2338644\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Background The prognosis for advanced intrahepatic cholangiocarcinoma (iCCA) is poor, and there remains an urgent need to develop efficient systemic therapy. The efficacy of Pembrolizumab immunotherapy combined with lenvatinibin in iCCA is still unclear. The role of Epstein–Barr-virus (EBV) as a biomarker in iCCA for response to immunotherapy needs further exploration. Case presentation We report a case of a 60-year-old female with EBV-associated advanced iCCA (EBVaiCCA) who progressed after first-line therapy. She accomplished an available response to the combination therapy of pembrolizumab with lenvatinib, with overall survival of 20 months. Conclusions As far as we know, this is the first case report about the application of Pembrolizumab with lenvatinib for EBVaiCCA patients. This case indicates that the combination of immunotherapy and antiangiogenic therapy provides a glimmer of hope for advanced EBVaiCCA patients.\",\"PeriodicalId\":4,\"journal\":{\"name\":\"ACS Applied Energy Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2024-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Energy Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/15384047.2024.2338644\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, PHYSICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Energy Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15384047.2024.2338644","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

摘要

ABSTRACT 背景晚期肝内胆管癌（iCCA）预后较差，目前仍急需开发高效的系统疗法。Pembrolizumab免疫疗法联合来伐替尼治疗iCCA的疗效尚不明确。EB病毒（Epstein-Barr-virus，EBV）作为生物标志物在iCCA中对免疫疗法反应的作用需要进一步探讨。病例介绍我们报告了一例患有 EBV 相关晚期 iCCA（EBVaiCCA）的 60 岁女性患者，她在接受一线治疗后病情出现进展。她对 pembrolizumab 和来伐替尼的联合治疗产生了反应，总生存期为 20 个月。结论据我们所知，这是第一例关于 EBVaiCCA 患者应用 Pembrolizumab 联合来伐替尼治疗的病例报告。该病例表明，免疫疗法和抗血管生成疗法的联合应用为晚期EBVaiCCA患者带来了一线希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Significant response to pembrolizumab plus lenvatinib in Epstein–Barr-virus-associated intrahepatic cholangiocarcinoma: a case report

ABSTRACT Background The prognosis for advanced intrahepatic cholangiocarcinoma (iCCA) is poor, and there remains an urgent need to develop efficient systemic therapy. The efficacy of Pembrolizumab immunotherapy combined with lenvatinibin in iCCA is still unclear. The role of Epstein–Barr-virus (EBV) as a biomarker in iCCA for response to immunotherapy needs further exploration. Case presentation We report a case of a 60-year-old female with EBV-associated advanced iCCA (EBVaiCCA) who progressed after first-line therapy. She accomplished an available response to the combination therapy of pembrolizumab with lenvatinib, with overall survival of 20 months. Conclusions As far as we know, this is the first case report about the application of Pembrolizumab with lenvatinib for EBVaiCCA patients. This case indicates that the combination of immunotherapy and antiangiogenic therapy provides a glimmer of hope for advanced EBVaiCCA patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ACS Applied Energy Materials Materials Science-Materials Chemistry

CiteScore

10.30

自引率

6.20%

发文量

1368

期刊介绍： ACS Applied Energy Materials is an interdisciplinary journal publishing original research covering all aspects of materials, engineering, chemistry, physics and biology relevant to energy conversion and storage. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrate knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important energy applications.